Measurement error in the timing of events: effect on survival analyses in randomized clinical trials
Authors:
- 6 September 2010
- journal article
- Published by SAGE Publications in Clinical Trials
- Vol. 7 (6) , 626-633
Abstract
Background Presence of measurement error in the outcome can complicate the interpretation of a randomized clinical trial. The Oncologic Drugs Advisory Committee of the US Food and Drug Administration voted against recommending approval of bevacizumab for the initial treatment of metastatic breast cancer; one of their major concerns was the presence of a large amount of nondifferential measurement error in the evaluation of progression-free survival, the primary outcome of the randomized clinical trial E2100. Purpose To investigate the effects of nondifferential measurement error in time-to-event outcomes on the conclusions of a proportional hazards analysis of a randomized clinical trial. Methods Simulations were performed showing effects of measurement error on the estimated treatment effect (hazard ratio) in a clinical trial. In some simulations, the measurement error structure from E2100 data was approximated; for other simulations, larger or smaller measurement error was considered. Results The bias in estimating the hazard ratio was very small using measurement error and a hazard ratio similar to E2100. Even with a larger nondifferential measurement error, the bias remained small when the hazard ratio was in a range commonly seen in clinical trials. There was no or little effect on the variability of the estimated treatment effect. Limitations Because of censoring issues, retrospective evaluation of the measurement error structure from a completed trial is difficult. Although our simulations cover a range of plausible measurement error values, in theory, a trial could have much larger measurement error than we considered. Differential measurement error is only briefly considered. Conclusions Nondifferential measurement error due to variability in estimating time-to-event outcomes will typically not be a major concern in randomized clinical trials.Keywords
This publication has 10 references indexed in Scilit:
- Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology TrialsJournal of Clinical Oncology, 2009
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Proposal for the Use of Progression-Free Survival in Unblinded Randomized TrialsJournal of Clinical Oncology, 2007
- When You Look Matters: The Effect of Assessment Schedule on Progression-Free SurvivalJNCI: Journal of the National Cancer Institute, 2007
- Analysis of progression‐free survival in oncology trials: some common statistical issuesPharmaceutical Statistics, 2007
- Discrete Proportional Hazards Models for Mismeasured OutcomesBiometrics, 2003
- Weibull Regression for Lifetimes Measured with ErrorLifetime Data Analysis, 1999
- Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observationJournal of Chronic Diseases, 1981